For Effient And Brilinta, A Formidable Competitor Grows More So
Plavix was a tough competitor before it went generic; now that cheap versions of the clot-buster are available, the market will prove even more challenging for the remaining branded antiplatelet drugs.
You may also be interested in...
Despite Lilly's decision not to make an indirect comparison its chosen comparator, AstraZeneca’s Brilinta, NICE agrees that Lilly's Efient is cost-effective and sometimes clinically superior to standard care.
AstraZeneca investors will have to wait two more months to hear details of CEO Pascal Soriot’s plans for re-energizing the struggling big pharma. But the new chief did discuss several near-term objectives for the company and what he has pinpointed as being some of the operational problems, based on discussion with hundreds of employees, during a year-end financial call Jan. 31.
A study published in the New England Journal of Medicine showed Effient was not superior to Plavix in treating patients who had not undergone revascularization.